CTAS vs ROIV · P/E 51, rev $11.26B vs rev $8.3M
Cintas Corporation (CTAS) versus Roivant Sciences Ltd (ROIV) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported ROIV revenue for 2026-03-31 was $8.3M. Net income was -$299.8M. Revenue was down 71.6% from 2025-03-31 to 2026-03-31. ROIV currently screens at market cap $7.47B.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. ROIV currently screens at market cap $7.47B.
Not investment advice. Open the CTAS and ROIV stock pages for the full models.
Not investment advice.